Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 5/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 4/20 | 0.44 |
| ▸ | MMP7 | P09237 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | MMP16 | P51512 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27464451 | 0.85 | HTT (0.50) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL16884985 | 0.85 | CA12 (0.51) | CA1CA2CA12CA9TSHR | |
| SCHEMBL27933104 | 0.83 | CA12 (0.50) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL8959071 | 0.83 | CA2 (0.54) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL22206134 | 0.83 | CA1 (0.54) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL1161572 | 0.83 | CA12 (0.54) | CA1CA2CA12CA9TSHR | |
| SCHEMBL28230363 | 0.83 | CA1 (0.54) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL11329369 | 0.83 | CA1 (0.49) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL8013573 | 0.82 | MMP2 (0.55) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL9772356 | 0.82 | CA12 (0.49) | CA1CA2CA12CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1227540-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY CO LTD (GB) | 1999-09-01 | — | — | CN | claimed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| EP-4234547-A2 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | US | disclosed |
| CN-105319848-B | Colored curable resin composition | 住友化学株式会社 | 2021-03-26 | — | — | CN | disclosed |
| EP-3793993-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | ARIAD Pharmaceuticals, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112313223-A | Pharmaceutically acceptable salts of pyrimidine derivatives and methods of treating conditions | 阿瑞雅德制药公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-103365080-B | Photosensitive composition | 住友化学株式会社 | 2019-04-26 | — | — | CN | disclosed |
| CN-106631927-B | A kind of synthetic method of 3- sulfonyl group propionic acid compounds | 济南大学 | 2019-02-19 | — | — | CN | disclosed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000031032-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
| US-6054254-A | COATING WITH PHOTORESISTS, EXPOSURE TO LIGHT, DEVELOPMENT | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-04-25 | — | — | US | disclosed |
| CN-1227540-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY CO LTD (GB) | 1999-09-01 | — | — | CN | disclosed |
| US-5372914-A | Pattern forming method | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-12-13 | — | — | US | disclosed |
| US-5348838-A | Photoresist | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4637833-A | OIL WELLS, GAS WELLS | PHILLIPS PETROLEUM CO. (US) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | DPYD, TYMP, TYMS | CA1 4866/4885CA2 3607/4885CA12 4763/4885 |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | DPYD, TYMP, TYMS | CA1 4876/4885CA2 3762/4885CA12 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.